|By PR Newswire||
|April 18, 2014 08:45 PM EDT||
PITTSBURGH, April 18, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that Supreme Court Chief Justice Roberts has denied Teva's application for an injunction seeking to prevent Mylan's launch of a generic version of Copaxone® pending the Supreme Court's decision on Teva's appeal. This is the second time that the Chief Justice has denied Teva's request for such an injunction.
In March, the Supreme Court granted Teva's petition for certiorari seeking clarification of the standard of review that appellate courts should apply when considering appeals relating to the construction of a patent claim. Oral argument is expected to be heard in the fall of 2014.
Mylan CEO Heather Bresch commented: "We are pleased with the Chief Justice's decision, and we look forward to introducing the first generic Copaxone® treatment for multiple sclerosis patients in the U.S. at market formation. Mylan remains eligible to receive approval from the U.S. Food and Drug Administration on May 25, 2014."
This press release includes statements that constitute "forward-looking statements," including with regard to litigation and sales of products. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: any legal or regulatory challenges to the settlement; strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
SOURCE Mylan Inc.
Sep. 30, 2016 02:45 AM EDT Reads: 2,422
Sep. 30, 2016 02:15 AM EDT Reads: 1,635
Sep. 30, 2016 02:00 AM EDT Reads: 1,378
Sep. 30, 2016 02:00 AM EDT Reads: 2,077
Sep. 30, 2016 01:45 AM EDT Reads: 2,185
Sep. 30, 2016 01:15 AM EDT Reads: 2,961
Sep. 30, 2016 12:45 AM EDT Reads: 2,976
Sep. 30, 2016 12:00 AM EDT Reads: 1,677
Sep. 30, 2016 12:00 AM EDT Reads: 2,378
Sep. 29, 2016 11:30 PM EDT Reads: 1,213
Sep. 29, 2016 10:30 PM EDT Reads: 4,058
Sep. 29, 2016 10:15 PM EDT Reads: 2,801
Sep. 29, 2016 10:00 PM EDT Reads: 1,814
Kubernetes is a new and revolutionary open-sourced system for managing containers across multiple hosts in a cluster. Ansible is a simple IT automation tool for just about any requirement for reproducible environments. In his session at @DevOpsSummit at 18th Cloud Expo, Patrick Galbraith, a principal engineer at HPE, discussed how to build a fully functional Kubernetes cluster on a number of virtual machines or bare-metal hosts. Also included will be a brief demonstration of running a Galera M...
Sep. 29, 2016 09:45 PM EDT Reads: 3,143
Why do your mobile transformations need to happen today? Mobile is the strategy that enterprise transformation centers on to drive customer engagement. In his general session at @ThingsExpo, Roger Woods, Director, Mobile Product & Strategy – Adobe Marketing Cloud, covered key IoT and mobile trends that are forcing mobile transformation, key components of a solid mobile strategy and explored how brands are effectively driving mobile change throughout the enterprise.
Sep. 29, 2016 08:45 PM EDT Reads: 2,225